Recently, compromise texts were agreed by the European Commission, Council and Parliament on new legislation on Medical Devices (MD) and on In Vitro Diagnostic (IVD) Medical Devices (MD). A key issue that remains to be dealt with is the reimbursement of diagnostic tests that are necessary to personalised medicines.
What might this mean for patients, and where is additional coordination between regulators, industry, patients and payers necessary?
Policy and Legal Officer,
Unit GROW D.4,
Melanoma Patient Network Europe
To download the slides, please click here.
Watch here the recording of the webinar.